我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

比索洛尔对慢性心功能不全患者血浆中降钙素基因相关肽和内皮素的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2002年第3期
页码:
243-244
栏目:
临床研究
出版日期:
2002-05-01

文章信息/Info

Title:
The effects of bisoprol on plasma calciton in gene relative peptide and endothel in level in patients with chronic heart failure
作者:
郑晓荣1;  王易虎1;  张灿久1;  许庆丽2
1.第四军医大学西京医院综合诊疗科, 陕西 西安 710032; 2.西安141医院心脏内科
Author(s):
ZHENG Xiao-rong1; WANG Yi-hu1;  ZHANG Can-jiu1;  XU Qing-li2
1.Department of Polyclinic,Xijing Hospital, Fourth Military Medical University,Xi’an, Shaanxi 710032, China; 2. Department of Cardiology, 141 Hospital
关键词:
降钙素基因相关肽;  内皮素21;  心力衰竭;  慢性;  比索洛尔
Keywords:
calcitonin gene-related peptide;  endothelin;  heart failure;  chronic;  bisoprol
分类号:
R541.4; R927　
DOI:
-
文献标识码:
A
摘要:
目的 探讨B受体阻制剂(比索洛尔) 对慢性心功能不全(心衰) 患者血浆降钙素基因相关肽(CGRP) 和内皮素21 (ET21) 的影响。方法 将符合本试验纳入标准的68 例心衰患者分成试验组30 例和对照组38 例, 两组患者均口服相同的或同类的基本抗心衰药物的治疗, 在此基础上试验组加服比索洛尔。测定患者试验初始时和服药6个月后血浆CGRP 和ET21 浓度。结果 两组患者血浆CGRP 和ET21 的浓度初始时无显著差异(P>0.05) , 试验组在6个月后血浆CGRP 和ET21 浓度与初始时比较, 均出现显著性差异(P<0.01) , 而对照组则均无显著性差异(P>0.05)。结论 慢性心衰患者在原有基本药物治疗的基础上加用比索洛尔, 可以降低心衰患者血浆中CGRP 和ET21 浓度, 对心衰患者的临床预后有益。
Abstract:
AIM To study the effects of bisoprol on plasma calcitonin gene-related peptide (CGRP) and endothelin-1 (ET-1) levels in patients with chronic heart failure.METHODS The patients were divided into the tested group and the control group who were taken same kinds or sorts of basic drugs for the heart failure. The venous plasma CGRP and ET-1 levels were determined at the beginning and 6 months later.RESULTS ①At the beginning there were no significantly different in the two groups for the levels of their plasma CGRP and ET-1.②In the tested group the levels of the plasma CGRP and ET-1 after 6 months were higher than at the beginning.③But in the control group there were no significant changes after 6 months.CONCLUSION Bisoprol added to other basic drugs can decreased the levels of the plasma CGRP and ET-1, furthermore, it was benefit for the prognosis of the patients with the heart failure.

参考文献/References

[1] CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol study II(CIBIS-II): A randomized trial[J].Lancet,1999, 353: 9-13.

[2]侯 凡,祝善俊,李隆贵,等.充血性心力衰竭患者血浆一氧化氮和内皮素等的改变[J].中华内科杂志, 1999, 38(5):306-308.

[3] Colucci WS. Myocardial endothelin. Does it play a role in myocardial failure? [J].Circulation, 1996, 93: 1069-1072.

[4] Shubeita HE, McDonough PM, Harris AN,et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and myocardial cell hypertrophy [J].J Biol Chem,1990,265:20555-20562.

[5]李 妍,贾国良.内皮素系统对心血管病的作用及临床意义[J].心功能杂志,1998, 10(5): 15-18.

备注/Memo

备注/Memo:
收稿日期：2001-10-23.
更新日期/Last Update: 2005-05-01